IL-31 monoclonal antibodies
US7531637B2 · kind B2 · utility
63Cited by
3References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2006 |
| Grant date | May 12, 2009 |
| Priority date | — |
| Expiry date | May 8, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.